Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in relapsed or refractory multiple myeloma Meeting Abstract


Authors: Hansen, D. K.; Peres, L. C.; Dima, D.; Richards, A.; Shune, L. O.; Afrough, A.; Midha, S.; Dhakal, B.; Kocoglu, M. H.; Atrash, S.; Ferreri, C.; Castaneda, O.; Davis, J. A.; Ouchveridze, E.; McGuirk, J. P.; Wagner, C. B.; Bansal, R.; Costello, P.; Smith, K.; Lieberman-Cribbin, A.; De Avila, G.; Purvey, S.; Hosoya, H.; Mikkilineni, L.; Oswald, L. B.; Kaur, G.; Pasvolsky, O.; Gaballa, M. R.; Herr, M. M.; Forsberg, P. A.; Janakiram, M.; Htut, M.; Asoori, S.; Kalariya, N.; Hashmi, H.; Reshef, R.; Sborov, D. W.; Nadeem, O.; Anwer, F.; Khouri, J.; Raza, S.; Atanackovic, D.; Alsina, M.; Freeman, C. L.; Locke, F. L.; Voorhees, P. M.; Anderson, L., Jr.; Richard, S.; Martin, T.; Lin, Y.; Patel, K. K.; Sidana, S.
Abstract Title: Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in relapsed or refractory multiple myeloma
Meeting Title: 66th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 144
Issue: Suppl. 1
Meeting Dates: 2024 Dec 7-10
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2024-11-05
Start Page: 936
End Page: 939
Language: English
ACCESSION: WOS:001412850300030
DOI: 10.1182/blood-2024-194390
PROVIDER: wos
Notes: Meeting Abstract -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hamza Hashmi
    61 Hashmi